[go: up one dir, main page]

CL2016003434A1 - Método ex vivo de pronóstico de metástasis en cáncer de próstata - Google Patents

Método ex vivo de pronóstico de metástasis en cáncer de próstata

Info

Publication number
CL2016003434A1
CL2016003434A1 CL2016003434A CL2016003434A CL2016003434A1 CL 2016003434 A1 CL2016003434 A1 CL 2016003434A1 CL 2016003434 A CL2016003434 A CL 2016003434A CL 2016003434 A CL2016003434 A CL 2016003434A CL 2016003434 A1 CL2016003434 A1 CL 2016003434A1
Authority
CL
Chile
Prior art keywords
metastases
prognosis
prostate cancer
vivo method
expression
Prior art date
Application number
CL2016003434A
Other languages
English (en)
Inventor
Cerda Infante Javier
MONTECINOS ACUÑA Viviana
Original Assignee
Pontificia Univ Catolia De Chile
Cerda Infante Javier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Univ Catolia De Chile, Cerda Infante Javier filed Critical Pontificia Univ Catolia De Chile
Priority to CL2016003434A priority Critical patent/CL2016003434A1/es
Priority to ES17887687T priority patent/ES2949875T3/es
Priority to PCT/CL2017/050095 priority patent/WO2018119544A1/es
Priority to CA3048551A priority patent/CA3048551C/en
Priority to US16/474,459 priority patent/US20190345563A1/en
Priority to EP17887687.6A priority patent/EP3564665B1/en
Publication of CL2016003434A1 publication Critical patent/CL2016003434A1/es
Priority to US18/636,932 priority patent/US20240301506A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/575—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método ex vivo de pronóstico de metástasis en cáncer de próstata que comprende determinar el nivel de expresión de al menos uno de los siguientes genes: NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 y GALNT16, en una muestra biológica que contenga células de estroma de tumor primario de cáncer de próstata; y establecer si la expresión de los genes está aumentada o disminuida, y correlacionarlo con el pronóstico de metástasis en CaP.
CL2016003434A 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata CL2016003434A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata
ES17887687T ES2949875T3 (es) 2016-12-30 2017-12-29 Método ex vivo de pronóstico de metástasis en cáncer de próstata
PCT/CL2017/050095 WO2018119544A1 (es) 2016-12-30 2017-12-29 Método ex vivo de pronóstico de metástasis en cáncer de próstata
CA3048551A CA3048551C (en) 2016-12-30 2017-12-29 Ex vivo method for the prognosis of metastasis in prostate cancer
US16/474,459 US20190345563A1 (en) 2016-12-30 2017-12-29 Ex-vivo method for the prognosis of metastasis in prostate cancer
EP17887687.6A EP3564665B1 (en) 2016-12-30 2017-12-29 Ex-vivo method for the prognosis of metastasis in prostate cancer
US18/636,932 US20240301506A1 (en) 2016-12-30 2024-04-16 Ex vivo method for the prognosis of metastasis in prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata

Publications (1)

Publication Number Publication Date
CL2016003434A1 true CL2016003434A1 (es) 2018-11-23

Family

ID=62706585

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata

Country Status (5)

Country Link
US (2) US20190345563A1 (es)
EP (1) EP3564665B1 (es)
CL (1) CL2016003434A1 (es)
ES (1) ES2949875T3 (es)
WO (1) WO2018119544A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8338109B2 (en) * 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20100233691A1 (en) * 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
EP2048242A1 (de) * 2007-10-08 2009-04-15 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Microarray für die Expressionsanalyse der zellulären Glykosylierungsmaschinerie
CA2745961A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2012129408A2 (en) * 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2014052930A2 (en) 2012-09-28 2014-04-03 The Regents Of The University Of California, Irvine Biomarkers for prostate cancer prognosis
EP2762574A1 (en) * 2013-01-31 2014-08-06 Fina Biotech, S.L. Non-invasive diagnostic method for diagnosing bladder cancer
CA2915823A1 (en) * 2013-06-19 2014-12-24 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis

Also Published As

Publication number Publication date
CA3048551A1 (en) 2018-07-05
US20190345563A1 (en) 2019-11-14
EP3564665A4 (en) 2020-12-02
EP3564665A1 (en) 2019-11-06
WO2018119544A1 (es) 2018-07-05
EP3564665B1 (en) 2023-05-03
ES2949875T3 (es) 2023-10-03
US20240301506A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
CO2017003528A2 (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
MX374827B (es) Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer.
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
CO2019011359A2 (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
BR112017005040A2 (pt) aparelho e sistema
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
JOP20190280A1 (ar) مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
IL280465A (en) Methods for gene modification of hematopoietic cells
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2019014661A (es) Variantes de b4galt1 y usos de estas.
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EP3460050A4 (en) CELL RENTAL PROCESS, CULTURAL MEDIUM AND CULTURE MEDIUM KIT